ANDOVER, Mass. , Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 37 th Annual Healthcare Conference at the Lotte New York Palace. The... Read More

ANDOVER, Mass. , Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 27, 2025 , TransMedics granted non-qualified stock options to purchase an aggregate of 27,582 shares of its common stock and an aggregate of 18,299 restricted... Read More

ANDOVER, Mass. , Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2025 . Recent Highlights Total revenue of $143.8 million in the third quarter of 2025, a 32% increase compared to the... Read More

ANDOVER, Mass. , Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025 . The TransMedics management team will host a corresponding... Read More

Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need TransMedics President and Chief Executive Officer, Waleed Hassanein , M.D., to discuss strategic collaboration at upcoming Italian Society for Organ and Tissue... Read More

ANDOVER, Mass. , Aug. 25, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Morgan Stanley 23 rd... Read More

ANDOVER, Mass. , Aug. 4, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its Investigational Device Exemption (IDE), allowing the company to proceed with the... Read More

ANDOVER, Mass. , Aug. 1, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 28, 2025 , TransMedics granted non-qualified stock options to purchase an aggregate of 21,458 shares of its common stock and an aggregate of 14,283 restricted... Read More

ANDOVER, Mass. , July 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2025 . Recent Highlights Total revenue of $157.4 million in the second quarter of 2025, a 38% increase compared to the second... Read More

ANDOVER, Mass. , July 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 45 th Annual Growth Conference at the InterContinental Boston Hotel. Management is... Read More

ANDOVER, Mass. , July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025 . The TransMedics management team will host a corresponding... Read More

ANDOVER, Mass. , May 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 21, 2025 , TransMedics granted non-qualified stock options to purchase an aggregate of 9,940 shares of its common stock and an aggregate of 6,670 restricted stock... Read More

ANDOVER, Mass. , May 20, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to present at the William Blair 45 th Annual Growth Stock... Read More

ANDOVER, Mass. , May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025 . Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first... Read More

ANDOVER, Mass. , April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025 . The TransMedics management team will host a corresponding... Read More

ANDOVER, Mass. , April 2, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on March 28, 2025 , TransMedics granted non-qualified stock options to purchase an aggregate of 1,570 shares of its common stock and an aggregate of 1,043 restricted... Read More

ANDOVER, Mass. , Feb. 27, 2025 /PRNewswire/ -- TransMedics Group, Inc . ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2024 . Recent Highlights Total revenue of $121.6 million in the fourth quarter of 2024, a 50% increase compared... Read More

ANDOVER, Mass. , Feb. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 45 th Annual... Read More

ANDOVER, Mass. , Feb. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025 . The TransMedics management team will host... Read More

ANDOVER, Mass. , Feb. 3, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on January 28, 2025 , TransMedics granted non-qualified stock options to purchase an aggregate of 34,884 shares of its common stock and an aggregate of 23,192 restricted... Read More

ANDOVER, Mass. , Jan. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion Capital on January 10, 2025 . In response, the company issued the... Read More

ANDOVER, Mass. , Dec. 23, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 43 rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025... Read More

ANDOVER, Mass. , Dec. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 9, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 20,612 shares of its common stock and an aggregate of 13,576 restricted... Read More

ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive... Read More

ANDOVER, Mass. , Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 AM ET . Waleed Hassanein , MD., President and Chief Executive Officer,... Read More

ANDOVER, Mass. , Nov. 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 36 th Annual Healthcare Conference at the Lotte New York Palace. The... Read More

ANDOVER, Mass. , Oct. 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 23, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 2,969 shares of its common stock and an aggregate of 1,937 restricted... Read More

ANDOVER, Mass. , Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024 . Recent Highlights Total revenue of $108.8 million in the third quarter of 2024, a 64% increase compared to the... Read More

ANDOVER, Mass. , Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday, October 28, 2024 . The TransMedics management team will host a corresponding... Read More

ANDOVER, Mass. , Sept. 27, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on September 24, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 336 shares of its common stock and an aggregate of 218 restricted... Read More

ANDOVER, Mass. , Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22 nd Annual Global Healthcare Conference at the Marriott Marquis New... Read More

ANDOVER, Mass. , Aug. 20, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on August 16, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 3,073 shares of its common stock and an aggregate of 2,003 restricted... Read More

ANDOVER, Mass. , July 31, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024 . Recent Highlights Total revenue of $114.3 million in the second quarter of 2024, a 118% increase compared to the second... Read More

ANDOVER, Mass. , July 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 44 th Annual Growth Conference at the InterContinental Boston Hotel. Management is... Read More

ANDOVER, Mass. , July 18, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 15, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 9,522 shares of its common stock and an aggregate of 6,240 restricted... Read More

ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024 . The TransMedics management team will host a corresponding... Read More

ANDOVER, Mass. , June 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on June 18, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 1,002 shares of its common stock and an aggregate of 657 restricted stock... Read More

ANDOVER, Mass. , May 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 14, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 18,320 shares of its common stock and an aggregate of 12,068 restricted... Read More

ANDOVER, Mass. , April 30, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024 . Recent Highlights Net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the first... Read More

ANDOVER, Mass. , April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024 . The TransMedics management team will host a corresponding... Read More

ANDOVER, Mass. , April 8, 2024 /PRNewswire/ -- TransMedics Group, Inc. ( "TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on April 4, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 9,722 shares of its common stock and an aggregate of 6,322 restricted... Read More

ANDOVER, Mass. , March 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on March 15, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 9,418 shares of its common stock and an aggregate of 6,149 restricted... Read More

ANDOVER, Mass. , Feb. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc . ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 44 th Annual... Read More

ANDOVER, Mass. , Feb. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 23, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 3,815 shares of its common stock and an aggregate of 2,479 restricted... Read More

ANDOVER, Mass. , Feb. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023 . Recent Highlights Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared... Read More

ANDOVER, Mass. , Feb. 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 14, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 4,041 shares of its common stock and an aggregate of 2,627 restricted... Read More

ANDOVER, Mass. , Feb. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2023 after market close on Monday, February 26, 2024 . The TransMedics management team will host a... Read More

ANDOVER, Mass. , Jan. 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on January 12, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 24,535 shares of its common stock and an aggregate of 15,817 restricted... Read More

ANDOVER, Mass. , Dec. 18, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 42 nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 8, 2024 ,... Read More

ANDOVER, Mass. , Dec. 12, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 7, 2023 , TransMedics granted non-qualified stock options to purchase an aggregate of 9,547 shares of its common stock and an aggregate of 6,175 restricted... Read More

ANDOVER, Mass. , Nov. 14, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 35 th Annual Healthcare Conference in New York . The fireside chat will... Read More

ANDOVER, Mass. , Nov. 6, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023 . Recent Highlights Net revenue of $66.4 million in the third quarter of 2023, a 159% increase compared to the third... Read More

ANDOVER, Mass. , Nov. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on November 1, 2023 , TransMedics granted non-qualified stock options to purchase an aggregate of 27,520 shares of its common stock and an aggregate of 17,670 restricted... Read More

ANDOVER, Mass. , Oct. 23, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2023 after market close on Monday, November 6, 2023 . The TransMedics management team will host a corresponding... Read More

ANDOVER, Mass. , Oct. 10, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 5, 2023 , TransMedics granted non-qualified stock options to purchase an aggregate of 105,119 shares of its common stock and an aggregate of 67,288 restricted... Read More

ANDOVER, Mass. , Aug. 28, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 21 st Annual Global Healthcare Conference at the Sheraton New York. The... Read More

ANDOVER, Mass. , Aug. 16, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the closing of its previously announced acquisition of Summit Aviation, a premier U.S. charter flight operator. The acquisition enables the establishment of TransMedics... Read More

ANDOVER, Mass. , Aug. 7, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on August 1, 2023 , TransMedics granted non-qualified stock options to purchase an aggregate of 48,112 shares of its common stock and an aggregate of 31,109 restricted... Read More

ANDOVER, Mass. , Aug. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2023 . Recent Highlights Net revenue of $52.5 million in the second quarter of 2023, a 156% increase compared to the second... Read More

NORTHBROOK, Ill. , Aug. 2, 2023 /PRNewswire/ -- Bridge to Life Ltd. (BTL), a leading global supplier of organ preservation and perfusion technologies, announced today its divestiture of certain assets to TransMedics, Inc., a wholly owned subsidiary of TransMedics Group, Inc. (NASDAQ: TMDX), including its EVOSS heart and lung and LifeCradle heart perfusion assets. BTL will use the proceeds from the divestiture of these assets... Read More

ANDOVER, Mass. , Aug. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that is has acquired from Bridge to Life Ltd. ("Bridge to Life"), assets and intellectual property related to the Ex-Vivo Organ Support System ("EVOSS") and LifeCradle Heart... Read More

Establishes the first national provider of air logistics dedicated to organ transplantation in the U.S. ANDOVER, Mass. , Aug. 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and... Read More

ANDOVER, Mass. , July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said... Read More

ANDOVER, Mass. , July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 43 rd Annual Growth Conference at the InterContinental Boston Hotel. Management is... Read More

ANDOVER, Mass. , July 20, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2023 after market close on Thursday, August 3, 2023 . The TransMedics management team will host a corresponding... Read More

ANDOVER, Mass. , May 30, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 24, 2023 , TransMedics granted non-qualified stock options to purchase an aggregate of 87,472 shares of its common stock and an aggregate of 30,565 restricted... Read More

ANDOVER, Mass. , May 30, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 24, 2023 , TransMedics granted non-qualified stock options to purchase an aggregate of 87,472 shares of its common stock and an aggregate of 30,565 restricted... Read More

ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the upsize and pricing of $400 million aggregate principal amount of convertible senior unsecured notes that will mature on June 1, 2028 , unless earlier redeemed, repurchased... Read More

ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior unsecured notes that will mature on June 1, 2028... Read More

ANDOVER, Mass. , May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023 . Recent Highlights Net revenue of $41.6 million in the first quarter of 2023, a 162% increase compared to the first... Read More

ANDOVER, Mass. , May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that it has published its inaugural Environmental, Social & Governance (ESG) report. "Our core mission is to transform organ transplantation and expand access to life-saving... Read More

ANDOVER, Mass. , April 17, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2023 after market close on Monday, May 1, 2023 . The TransMedics management team will host a corresponding... Read More

ANDOVER, Mass. , Feb. 24, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 20, 2023 , TransMedics granted non-qualified stock options to purchase an aggregate of 72,774 shares of its common stock to seven employees and an aggregate... Read More

ANDOVER, Mass. , Feb. 22, 2023 /PRNewswire/ - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2022 . Recent Highlights Total revenue of $31.4 million in the fourth quarter of 2022, a 225% increase compared to... Read More

ANDOVER, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Cowen 43 r d Annual... Read More

ANDOVER, Mass. , Feb. 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2022 after market close on Wednesday, February 22, 2023 . The TransMedics management team will host... Read More

ANDOVER, Mass. , Feb. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Nick Corcoran as Senior Vice President of Supply Chain and Operations, effective immediately. "Nick has extensive end-to-end supply chain and operations... Read More

ANDOVER, Mass. , Dec. 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 41 st Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, January 11,... Read More